Celgene boosts Q4 sales by 24% on stalwart Revlimid, up-and-coming Otezla

Celgene's ($CELG) fourth-quarter sales grew by 24% to $2.5 billion, taking full-year revenue up to $9.25 billion, a 21% hike; it's expecting another sales leap for 2016--albeit slightly smaller--with a forecast of $10.5 billion to $11 billion. Its new drug Otezla chipped in $183 million for the quarter. Release